DUX4 anticorps (AA 53-120)

N° du produit ABIN1713487

Cet anticorps Lapin Polyclonal détecte spécifiquement DUX4 dans WB, ELISA, IHC (p), IF (cc), IF (p), ICC et IHC (fro). Il présente une réactivité envers Humain.

Aperçu rapide pour DUX4 anticorps (AA 53-120) (ABIN1713487)

Antigène: DUX4 (Double Homeobox 4 (DUX4))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp DUX4 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-DUX4 anticorps

Épitope: AA 53-120

Homologie: Human

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human DUX4

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Détails sur DUX4

Antigène: DUX4 (Double Homeobox 4 (DUX4))

Autre désignation: DUX4

Sujet:

Synonyms: Double homeobox protein 10, Double homeobox protein 4, Double homeobox protein 4/10, DUX10, DUX4_HUMAN.

Background: DUX4 is a homeodomain protein with a similar protein sequence to Pax3 and Pax7. Defects in DUX4 may be the cause of facioscapulohumeral muscular dystrophy (FSHD). FSHD is characterized by weakness of the muscles of the face, upper-arm and shoulder girdle. Severity is highly variable. Weakness is slowly progressive and about 20 % of affected individuals eventually require a wheelchair. Approximately 70-90 % of individuals have inherited the disease-causing deletion from a parent, and approximately 10-30 % of affected individuals have FSHD as the result of a de novo deletion. Offsprings of an affected individual have a 50 % chance of inheriting the deletion.